156 related articles for article (PubMed ID: 36683866)
1. Pemafibrate therapy for non-alcoholic fatty liver disease is more effective in lean patients than obese patients.
Shinozaki S; Tahara T; Miura K; Lefor AK; Yamamoto H
Clin Exp Hepatol; 2022 Dec; 8(4):278-283. PubMed ID: 36683866
[TBL] [Abstract][Full Text] [Related]
2. Pemafibrate improves hepatic inflammation, function and fibrosis in patients with non-alcoholic fatty liver disease: a one-year observational study.
Shinozaki S; Tahara T; Lefor AK; Ogura M
Clin Exp Hepatol; 2021 Jun; 7(2):172-177. PubMed ID: 34295984
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of One-Year Pemafibrate Therapy on Non-Alcoholic Fatty Liver Disease Refractory to Long-Term Sodium Glucose Cotransporter-2 Inhibitor Therapy: A Pilot Study.
Shinozaki S; Tahara T; Miura K; Lefor AK; Yamamoto H
Life (Basel); 2023 Jun; 13(6):. PubMed ID: 37374110
[No Abstract] [Full Text] [Related]
4. Pemafibrate decreases markers of hepatic inflammation in patients with non-alcoholic fatty liver disease.
Shinozaki S; Tahara T; Lefor AK; Ogura M
Clin Exp Hepatol; 2020 Sep; 6(3):270-274. PubMed ID: 33145434
[TBL] [Abstract][Full Text] [Related]
5. Gamma-glutamyl transferase predicts pemafibrate treatment response in non-alcoholic fatty liver disease.
Takahashi Y; Seko Y; Yamaguchi K; Takeuchi K; Yano K; Kataoka S; Moriguchi M; Itoh Y
J Gastroenterol Hepatol; 2023 Oct; 38(10):1743-1749. PubMed ID: 37221601
[TBL] [Abstract][Full Text] [Related]
6. A Comparison of Alanine Aminotransferase Normalization between Pemafibrate and Bezafibrate in Patients with Nonalcoholic Fatty Liver Disease.
Yamada-Shimizu M; Tamaki N; Kurosaki M; Uchihara N; Suzuki K; Tanaka Y; Miyamoto H; Ishido S; Nobusawa T; Matsumoto H; Keitoku T; Higuchi M; Takaura K; Tanaka S; Maeyashiki C; Yasui Y; Takahashi Y; Tsuchiya K; Nakanishi H; Izumi N
Intern Med; 2024 May; 63(9):1185-1190. PubMed ID: 37779070
[TBL] [Abstract][Full Text] [Related]
7. Effect of pemafibrate on liver enzymes and shear wave velocity in non-alcoholic fatty liver disease patients.
Sugimoto R; Iwasa M; Eguchi A; Tamai Y; Shigefuku R; Fujiwara N; Tanaka H; Kobayashi Y; Ikoma J; Kaito M; Nakagawa H
Front Med (Lausanne); 2023; 10():1073025. PubMed ID: 36824614
[TBL] [Abstract][Full Text] [Related]
8. Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), versus placebo in patients with non-alcoholic fatty liver disease.
Nakajima A; Eguchi Y; Yoneda M; Imajo K; Tamaki N; Suganami H; Nojima T; Tanigawa R; Iizuka M; Iida Y; Loomba R
Aliment Pharmacol Ther; 2021 Nov; 54(10):1263-1277. PubMed ID: 34528723
[TBL] [Abstract][Full Text] [Related]
9. Pemafibrate Dramatically Ameliorated the Values of Liver Function Tests and Fibrosis Marker in Patients with Non-Alcoholic Fatty Liver Disease.
Ikeda S; Sugihara T; Hoshino Y; Matsuki Y; Nagahara T; Okano JI; Kitao S; Fujioka Y; Yamamoto K; Isomoto H
Yonago Acta Med; 2020 Aug; 63(3):188-197. PubMed ID: 32884438
[TBL] [Abstract][Full Text] [Related]
10. Pemafibrate improves liver dysfunction and non-invasive surrogates for liver fibrosis in patients with non-alcoholic fatty liver disease with hypertriglyceridemia: a multicenter study.
Morishita A; Oura K; Takuma K; Nakahara M; Tadokoro T; Fujita K; Tani J; Shi T; Himoto T; Tatsuta M; Moriya A; Senoo T; Tsutsui A; Nagano T; Takaguchi K; Ono M; Masaki T
Hepatol Int; 2023 Jun; 17(3):606-614. PubMed ID: 36583842
[TBL] [Abstract][Full Text] [Related]
11. Effect of a combination of pemafibrate and a mild low-carbohydrate diet on obese and non-obese patients with metabolic-associated fatty liver disease.
Suzuki Y; Maekawa S; Yamashita K; Osawa L; Komiyama Y; Nakakuki N; Takada H; Muraoka M; Sato M; Takano S; Fukasawa M; Yamaguchi T; Funayama S; Morisaka H; Onishi H; Enomoto N
J Gastroenterol Hepatol; 2023 Jun; 38(6):921-929. PubMed ID: 36811251
[TBL] [Abstract][Full Text] [Related]
12. Effects of body composition and liver function after long-term pemafibrate treatment on dyslipidemia-associated non-alcoholic fatty liver disease.
Ishikawa T; Terai N; Igarashi T; Yamazaki S; Kobayashi T; Sato T; Iwanaga A; Sano T; Yokoyama J; Honma T
Clin Exp Hepatol; 2023 Jun; 9(2):172-178. PubMed ID: 37502434
[TBL] [Abstract][Full Text] [Related]
13. Effect of pemafibrate on fatty acid levels and liver enzymes in non-alcoholic fatty liver disease patients with dyslipidemia: A single-arm, pilot study.
Seko Y; Yamaguchi K; Umemura A; Yano K; Takahashi A; Okishio S; Kataoka S; Okuda K; Moriguchi M; Okanoue T; Itoh Y
Hepatol Res; 2020 Dec; 50(12):1328-1336. PubMed ID: 32926754
[TBL] [Abstract][Full Text] [Related]
14. Clinical Characteristics and Metabolic Profiles of Non-Alcoholic Fatty Liver Disease (NAFLD) in Lean Patients and Their Comparison with Obese and Overweight NAFLD.
Chakrabarty M; Jha AN; Sharma DJ
J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443531
[TBL] [Abstract][Full Text] [Related]
15. Effect of 48-week pemafibrate on non-alcoholic fatty liver disease with hypertriglyceridemia, as evaluated by the FibroScan-aspartate aminotransferase score.
Hatanaka T; Kosone T; Saito N; Takakusagi S; Tojima H; Naganuma A; Takagi H; Uraoka T; Kakizaki S
JGH Open; 2021 Oct; 5(10):1183-1189. PubMed ID: 34622006
[TBL] [Abstract][Full Text] [Related]
16. A Significant Effect of Pemafibrate on Hepatic Steatosis and Fibrosis Indexes in Patients With Hypertriglyceridemia.
Katsuyama H; Yanai H; Adachi H; Hakoshima M
Gastroenterology Res; 2023 Aug; 16(4):240-243. PubMed ID: 37691751
[TBL] [Abstract][Full Text] [Related]
17. Pemafibrate, a selective PPARα modulator, prevents non-alcoholic steatohepatitis development without reducing the hepatic triglyceride content.
Sasaki Y; Asahiyama M; Tanaka T; Yamamoto S; Murakami K; Kamiya W; Matsumura Y; Osawa T; Anai M; Fruchart JC; Aburatani H; Sakai J; Kodama T
Sci Rep; 2020 May; 10(1):7818. PubMed ID: 32385406
[TBL] [Abstract][Full Text] [Related]
18. Non-alcoholic fatty liver disease (NAFLD) in lean individuals - Single centre large cohort clinicopathologic and immunophenotypic study.
Rastogi A; Rath I; Varadarajan A; Ramakrishna G; Bihari C; Maiwall R
Pathol Res Pract; 2022 Oct; 238():154112. PubMed ID: 36126451
[TBL] [Abstract][Full Text] [Related]
19. Higher Responsiveness for Women, High Transaminase Levels, and Fat Percentage to Pemafibrate Treatment for NAFLD.
Iwadare T; Kimura T; Kunimoto H; Tanaka N; Wakabayashi SI; Yamazaki T; Okumura T; Kobayashi H; Yamashita Y; Sugiura A; Joshita S; Umemura T
Biomedicines; 2022 Nov; 10(11):. PubMed ID: 36359326
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic Efficacy of Serum Mac-2 Binding Protein Glycosylation Isomer and Other Markers for Liver Fibrosis in Non-Alcoholic Fatty Liver Diseases.
Jang SY; Tak WY; Park SY; Kweon YO; Lee YR; Kim G; Hur K; Han MH; Lee WK
Ann Lab Med; 2021 May; 41(3):302-309. PubMed ID: 33303715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
